West Pharmaceutical Services, Inc. (NYSE:WST) Stake Boosted by Blair William & Co. IL

Blair William & Co. IL boosted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 10.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 112,520 shares of the medical instruments supplier’s stock after buying an additional 10,654 shares during the period. Blair William & Co. IL owned about 0.16% of West Pharmaceutical Services worth $37,063,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Fidelis Capital Partners LLC purchased a new position in shares of West Pharmaceutical Services in the first quarter worth approximately $27,000. Crewe Advisors LLC boosted its stake in West Pharmaceutical Services by 322.7% in the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the period. Quarry LP grew its position in West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after purchasing an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. acquired a new stake in West Pharmaceutical Services during the 1st quarter valued at $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at $40,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $309.20 on Thursday. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The stock has a market cap of $22.43 billion, a PE ratio of 40.79, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. The business has a fifty day simple moving average of $304.36 and a 200-day simple moving average of $338.16.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. During the same quarter in the previous year, the business posted $2.11 earnings per share. The company’s revenue was down 6.9% compared to the same quarter last year. On average, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.53% of the stock is currently owned by insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.